

PHARMESIS INTERNATIONAL LTD.
(the “**Company**”)
(Incorporated in the Republic of Singapore)
(Co. Registration No.: 200309641E)

**COMPLETION OF THE ACQUISITION OF
REMAINING 19% OF THE EQUITY INTEREST IN THE COMPANY’S 81%
SUBSIDIARY, SICHUAN LONGLIFE**

The Board refers to the announcement made on 23 September 2024 in relation to the entry by 成都国嘉联合制药有限公司 (Chengdu Kinna Pharmaceutical Co., Ltd) (the “**Purchaser**”), a wholly-owned subsidiary of the Company, into a conditional sale and purchase agreement to acquire the remaining 19% of the equity interest in the registered capital of 四川古蔺肝苏药业有限公司 (Sichuan Longlife Pharmaceutical Co., Ltd) (“**Sichuan Longlife**”) from 成都国嘉投资股份有限公司 (Chengdu Kinna Investment Co., Ltd.) (the “**Proposed Acquisition**”).

The Board wishes to announce that the Proposed Acquisition has been completed. Accordingly, the Purchaser’s equity interest in the registered capital of Sichuan Longlife has increased from 81% to 100% and Sichuan Longlife has become a wholly-owned subsidiary of the Purchaser.

BY ORDER OF THE BOARD

Wu Xuedan
Executive Director and Chief Executive Officer

30 September 2024